Abstract: The disclosure generally relates to the preparation of representative samples from clinical samples, e.g., tumors (whole or in part), lymph nodes, metastases, cysts, polyps, or a combination or portion thereof, using mechanical and/or biochemical dissociation methods to homogenize intact samples or large portions thereof. The resulting homogenate provides the ability to obtain a correct representative sample despite spatial heterogeneity within the sample, increasing detection likelihood of low prevalence subclones, and is suitable for use in various diagnostic assays as well as the production of therapeutics, especially “personalized” anti-tumor vaccines or immune cell based therapies.

Abstract: The present disclosure provides a method of separating cellular particles from a tissue sample and then sorting the cellular particles into two or more cellular particle populations.

Abstract: The present disclosure provides a method of separating cellular particles from a tissue sample and then sorting the cellular particles into two or more cellular particle populations.

Abstract: The present disclosure is directed to conjugates of a specific binding entity and an oligomer, i.e. [Specific Binding Entity]-[Oligomer]n, wherein n is an integer ranging from 1 to 12, and where the Oligomer includes, in some embodiments, a PNA sequence having at least one substituent at a gamma carbon position. In some embodiments, the substituent at the gamma carbon position, e.g. an amino acid, a peptide, a miniPEG, or a polymer, includes at least one reporter moiety.

Abstract: The disclosure is directed to conjugates, e.g. PNA conjugates, as well as methods of employing the conjugates for detecting one or more targets in a biological sample, e.g. a tissue sample.

Abstract: The invention is a method of identifying a cognate antigen for a T-cell receptor using neoantigens from a patient's tumor cells combined with the patient's T-cells and using cell sorting, genome sequencing, expressing TCR genes, presenting tumor neoantigens on MHC complex and uniquely barcoding the T-cells where TCR recognition occurs to tag all components of the TCR recognition complex.

Abstract: The present disclosure is directed to conjugates of a specific binding entity and an oligomer, i.e. [Specific Binding Entity]-[Oligomer]n, wherein n is an integer ranging from 1 to 12, and where the Oligomer includes, in some embodiments, a PNA sequence having at least one substituent at a gamma carbon position. In some embodiments, the substituent at the gamma carbon position, e.g. an amino acid, a peptide, a miniPEG, or a polymer, includes at least one reporter moiety.

Abstract: The disclosure is directed to conjugates, e.g. PNA conjugates, as well as methods of employing the conjugates for detecting one or more targets in a biological sample, e.g. a tissue sample.

Abstract: The invention is a method of identifying a cognate antigen for a T-cell receptor using neoantigens from a patient's tumor cells combined with the patient's T-cells and using cell sorting, genome sequencing, expressing TCR genes, presenting tumor neoantigens on MHC complex and uniquely barcoding the T-cells where TCR recognition occurs to tag all components of the TCR recognition complex.

Abstract: Disclosed herein is a method of analyzing flow cytometry data for cells derived from homogenized whole tumor samples.

Abstract: The present disclosure is directed to conjugates of a specific binding entity and an oligomer, i.e. [Specific Binding Entity]-[Oligomer]n, wherein n is an integer ranging from 1 to 12, and where the Oligomer includes, in some embodiments, a PNA sequence having at least one substituent at a gamma carbon position. In some embodiments, the substituent at the gamma carbon position, e.g. an amino acid, a peptide, a miniPEG, or a polymer, includes at least one reporter moiety.

Abstract: The disclosure is directed to conjugates, e.g. PNA conjugates, as well as methods of employing the conjugates for detecting one or more targets in a biological sample, e.g. a tissue sample.

Abstract: The disclosure generally relates to the preparation of representative samples from clinical samples, e.g., tumors (whole or in part), lymph nodes, metastases, cysts, polyps, or a combination or portion thereof, using mechanical and/or biochemical dissociation methods to homogenize intact samples or large portions thereof. The resulting homogenate provides the ability to obtain a correct representative sample despite spatial heterogeneity within the sample, increasing detection likelihood of low prevalence subclones, and is suitable for use in various diagnostic assays as well as the production of therapeutics, especially “personalized” anti-tumor vaccines or immune cell based therapies.

Abstract: The present disclosure provides a method of separating cellular particles from a tissue sample and then sorting the cellular particles into two or more cellular particle populations.

Abstract: Systems and methods for the activation of species and/or the delivery of species to a target environment using harmonic generation materials are generally described.

Abstract: Systems and methods for the activation of species and/or the delivery of species to a target environment using harmonic generation materials are generally described.

Abstract: A device and method for detecting the hybridization of an unmodified target deoxyribonucleic acid (DNA) molecule including exposing a Raman substrate to the unmodified target DNA molecule, where the unmodified target DNA molecule is a complementary DNA molecule to a thiol-terminated probe DNA molecule covalently linked to the Raman substrate. Also, the thiol-terminated probe DNA molecule includes an adenine analog substituted for adenine. The hybridization of the unmodified target DNA molecule to the thiol-terminated probe DNA molecule is detected by measuring a Raman spectroscopic response of the Raman substrate.

Abstract: Disclosed herein are novel targeted drug delivery and controlled release methods and compositions where optically absorbing nanoparticles, such as nanoshells, are functionalized on their surfaces with thermolabile molecules that bind the drug molecules to be delivered. The linkage between the thermolabile moiety on the nanoparticles and the drug is deliberately designed or selected to be temperature sensitive, so that upon illumination of the nanoparticle at a wavelength of light, the drug molecules on the nanoparticles will be released. Targeting molecules, such as antibodies, aptamers or other molecules like folic acid, can be concurrently bound to the nanoparticle surface to deliver the nanoparticle to specifically targeted cells or tissues prior to the photothermally induced drug release. In this way the nanoparticles can be advantageously concentrated on the target prior to illumination, which makes the disclosed compositions both a targeted delivery and a controllable drug release vehicle.